{"entity":{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","aka":[],"tldr":"Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies.","summary":"Andrea Necchi led PURE-01, which showed neoadjuvant pembrolizumab alone produces pathological complete responses in more than a third of muscle-invasive bladder cancers and defined biomarkers of response, and is a lead investigator of the KEYNOTE-057 and SunRISe programmes in non-muscle-invasive disease. He heads GU oncology at San Raffaele and studies bladder-sparing strategies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Necchi%20A%5BAuthor%5D%20bladder%20pembrolizumab"}],"tags":["urothelial","neoadjuvant","italy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["san-raffaele"],"pathways":[],"terms":[],"trials":["sunrise-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-sunrise-1-jco-2025"],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Head of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital; Professor, Vita-Salute San Raffaele University","institutionId":"san-raffaele","specialisms":["Urothelial cancer","Neoadjuvant immunotherapy","Bladder preservation","Non-muscle-invasive disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Necchi%20A%5BAuthor%5D%20bladder%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01)","journal":"JCO","year":2018,"doi":"10.1200/JCO.18.01148"},{"title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","journal":"European Urology","year":2020,"doi":"10.1016/j.eururo.2019.10.026"},{"title":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","journal":"Journal of Clinical Oncology","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SunRISe-1+TAR-200+BCG-unresponsive"}],"orcid":"0000-0002-3007-2756"},"route":"/people/andrea-necchi/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/"}],"trial":[{"id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/"}],"paper":[{"id":"paper-sunrise-1-jco-2025","kind":"paper","name":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-sunrise-1-jco-2025/"}],"journal":[{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/"}]}}